Climb Bio, Inc.

NasdaqGM:CLYM 株式レポート

時価総額：US$735.2m

Climb Bio バランスシートの健全性

財務の健全性 基準チェック /66

Climb Bioの総株主資本は$148.1M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$152.4Mと$4.3Mです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオn/a
現金US$109.56m
エクイティUS$148.09m
負債合計US$4.29m
総資産US$152.37m

財務の健全性に関する最新情報

分析記事 • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Recent updates

Seeking Alpha • Jul 23

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

Summary Climb Bio has surged >160% YTD, driven by anticipation for pivotal Phase 2/1b data in pMN, ITP, and SLE due by year-end 2026. Budoprutug, a CD19-targeting monoclonal antibody, has shown promising early safety and efficacy signals across multiple autoimmune indications, with Fast Track status in pMN. CLYM’s strong cash position ($146.3m, no significant debt) supports operations into 2028, but future Phase 3 trials will likely require dilutive capital raises. Upcoming data readouts are high-stakes; positive results could drive further upside, while underwhelming data may cause the stock to lose up to half its value. Read the full article on Seeking Alpha
分析記事 • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Summary Eliem Therapeutics, founded in 2019, shifted focus to autoimmune diseases with the acquisition of Tenet Medicines and its lead molecule, budoprutug. Budoprutug targets CD19-positive B cells, aiming to treat SLE, ITP, and MN by reducing pathogenic autoantibodies and improving disease symptoms. Early clinical trials for MN showed promising results, with 60% of patients achieving complete remission of proteinuria, supporting further development. Despite a decent market cap and cash reserves, ELYM's early-stage status and single-molecule focus make it a cautious watch rather than an immediate investment. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia. Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million. Read the full article on Seeking Alpha
分析記事 • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 15

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$0.56 misses by $0.09. Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of ETX-810, the company’s current cash, cash equivalents and short- and long-term marketable securities are now expected to fund operations into 2025.
Seeking Alpha • Aug 02

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Clinical-stage biotech Eliem Therapeutics (NASDAQ:ELYM) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS). The results indicated that ETX-810 did not indicate a statistically significant separation from the placebo in the primary endpoint, according to the company. The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
Seeking Alpha • Jul 11

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

SVB Leerink on Monday cut its price target on Eliem Therapeutics (NASDAQ:ELYM) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The brokerage reiterated its Outperform rating, in-line with sell-side rating of Strong Buy. "Given the decreased bioavailability of ETX-155 observed in the phase 1b interim data readout in photosensitive epilepsy, we lowered our POS for all ETX-155 programs, which resulted in our PT moving to $9," analyst Marc Goodman wrote in a note to clients. "We still expect data from ETX-810 in lumbosacral radicular pain in Q3, although expectations are low after the failed phase 2 study in diabetic peripheral neuropathy," he added. ELYM stock, which fell as much as 5.4% on Monday, has declined 67.3% YTD.

財務状況分析

短期負債: CLYMの 短期資産 ( $113.4M ) が 短期負債 ( $4.1M ) を超えています。

長期負債: CLYMの短期資産 ( $113.4M ) が 長期負債 ( $216.0K ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: CLYMは負債がありません。

負債の削減: CLYM過去 5 年間負債を抱えていません。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: CLYMは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。

キャッシュランウェイの予測: CLYMは、フリー キャッシュ フローが毎年5.9 % の歴史的率で減少し続ける場合、 1.1年間十分なキャッシュ ランウェイを有しています。

健全な企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/27 18:04
終値2026/07/27 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Climb Bio, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16

アナリスト機関
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG